Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction

Area of Science:

• Molecular biology
• Biochemistry
• Cancer research
• Infectious disease research

Background:

• Phospholipase A and acyltransferase (PLAAT) 4, also known as tazarotene-induced gene 3 (TIG3) or retinoic acid receptor responder 3 (RARRES3), is a class II tumor suppressor.
• Initially recognized for its role in retinoic acid signaling and tumor suppression, PLAAT4 has emerged as a critical enzyme in innate immunity.
• Its functions extend to antiviral and antiparasitic defense mechanisms, acting downstream of interferon regulatory factor 1 (IRF1) and interferons (IFNs).

Purpose of the Study:

• To provide a historical overview of PLAAT4 discovery and its evolving understanding.
• To summarize the transcriptional regulation of PLAAT4.
• To elucidate the molecular mechanisms underlying PLAAT4's roles in tumor prevention and anti-pathogen defense, and discuss therapeutic potential.

Main Methods:

• Literature review and synthesis of existing research findings on PLAAT4.
• Analysis of transcriptional regulation pathways involving IRF1 and retinoic acid signaling.
• Discussion of proposed molecular mechanisms for tumor suppression and antimicrobial activity.

Main Results:

• PLAAT4 exhibits dual functions as a tumor suppressor and an antimicrobial effector.
• Its activity is regulated by retinoic acid signaling in cancer contexts and by IRF1/IFNs in infectious disease contexts.
• The enzyme's phospholipid-metabolizing ability is central to its diverse biological roles.

Conclusions:

• PLAAT4 is a pleiotropic enzyme with significant implications for both cancer therapy and infectious disease treatment.
• Further research into PLAAT4's molecular mechanisms is warranted to develop targeted therapeutic strategies.
• Understanding PLAAT4 offers potential for novel treatments addressing both oncological and infectious pathologies.